Cargando…

Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP

INTRODUCTION: Frequent infusions and bleeds can impact on the health‐related quality of life (HRQoL) of paediatric haemophilia B patients. rIX‐FP (IDELVION(®)) is a fusion protein linking recombinant factor IX with recombinant albumin, and is associated with low bleeding rates with a weekly regimen,...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Mackensen, Sylvia, Shah, Jinesh, Seifert, Wilfried, Kenet, Gili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916427/ https://www.ncbi.nlm.nih.gov/pubmed/30427091 http://dx.doi.org/10.1111/hae.13624

Ejemplares similares

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B
por: Gill, Joan C., et al.
Publicado: (2019)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
por: Tagliaferri, Annarita, et al.
Publicado: (2022)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
por: López‐Jaime, Francisco José, et al.
Publicado: (2023)

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
por: Díaz‐Jordán, Bolívar Luis, et al.
Publicado: (2023)

Quanty4RIXS: a program for crystal field multiplet calculations of RIXS and RIXS–MCD spectra using Quanty
por: Zimmermann, Patric, et al.
Publicado: (2018)

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
por: Aiello, Andrea, et al.
Publicado: (2020)

Mr. William Howells Rix
Publicado: (1910)

Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY)
por: Riva, Silvia, et al.
Publicado: (2010)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update
por: Aiello, Andrea, et al.
Publicado: (2022)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

IRIXS Spectrograph: an ultra high-resolution spectrometer for tender RIXS
por: Bertinshaw, Joel, et al.
Publicado: (2021)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS)
por: Mahlangu, Johnny, et al.
Publicado: (2019)

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023)

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company
por: Hay, Charles R. M., et al.
Publicado: (2020)

R&D challenges in FP7
por: Delahaye, P, et al.
Publicado: (2008)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Synovitis and synovectomy in haemophilia
por: van Vulpen, Lize F. D., et al.
Publicado: (2020)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries
por: Plosker, Greg L.
Publicado: (2012)

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
por: Knoll, Stefanie, et al.
Publicado: (2013)

hv (2)-concept breaks the photon-count limit of RIXS instrumentation
por: Zhou, Ke-Jin, et al.
Publicado: (2020)

The FP420 R&D Project at the LHC
por: Cox, B.E.
Publicado: (2006)

Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4
por: Sack, B K, et al.
Publicado: (2015)

Cryo-EM structure of the essential ribosome assembly AAA-ATPase Rix7
por: Lo, Yu-Hua, et al.
Publicado: (2019)

Transmission zone plates as analyzers for efficient parallel 2D RIXS-mapping
por: Marschall, Felix, et al.
Publicado: (2017)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea
por: Baek, Hee Jo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9q6vnecib2o566hb7hcu2hi4e8